Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.42 |
| ▸ | CD44 | P16070 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HK1 | P19367 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GALK1 | P51570 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL44824 | 0.79 | HTR5A (0.53) | ALOX15HSD17B10CA12CA9GAA | |
| SCHEMBL88899 | 0.77 | ALOX15 (0.56) | ALOX15HSD17B10CA12CA9PNMT | |
| SCHEMBL14061414 | 0.72 | CA12 (0.56) | ALOX15HSD17B10CA12CA9PNMT | |
| SCHEMBL89255 | 0.72 | CA12 (0.56) | ALOX15HSD17B10CA12CA9GAA | |
| SCHEMBL13801620 | 0.69 | ADRA2A (0.38) | HSD17B10CA12CA9KDM4EMEN1 | |
| SCHEMBL29351494 | 0.69 | — | — | |
| SCHEMBL13590042 | 0.69 | PNMT (0.65) | ALOX15HSD17B10PNMTCD44MAOB | |
| SCHEMBL29374426 | 0.69 | PNMT (0.50) | ALOX15HSD17B10CA12CA9PNMT | |
| SCHEMBL10612 | 0.69 | — | — | |
| SCHEMBL214465 | 0.69 | PNMT (0.50) | ALOX15HSD17B10CA12CA9PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | ERMIUM THERAPEUTICS (FR) | 2024-01-18 | — | — | US | disclosed |
| EP-4217353-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | Ermium Therapeutics (FR) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022064075-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | ERMIUM THERAPEUTICS (FR) | 2022-03-31 | — | — | WO | disclosed |
| US-20160130282-A1 | MERCAPTOAMIDINE DERIVATIVES AND METHODS OF USE | ABBVIE INC. | 2016-05-12 | — | — | US | disclosed |
| US-9181275-B2 | Mercaptoamidine derivatives and methods of use | ABBVIE INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20130040940-A1 | MERCAPTOAMIDINE DERIVATIVES AND METHODS OF USE | ABBVIE INC. (US) | 2013-02-14 | — | — | US | disclosed |
| EP-0475527-B1 | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | SANOFI SA (FR) | 1998-02-25 | — | — | EP | disclosed |
| US-5624922-A | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1997-04-29 | — | — | US | disclosed |
| EP-0597540-B1 | Aryl-fused and hetaryl-fused-2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC (US) | 1996-06-05 | — | — | EP | disclosed |
| US-5380721-A | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0597540-A1 | Aryl-fused and hetaryl-fused-2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1994-05-18 | — | — | EP | disclosed |
| EP-0475527-A2 | Aryl-fused and hetaryl-fused-2, 4-diazepine and 2, 4-diazocine antiarrhythmic agents | STERLING DRUG INC. (US) | 1992-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040940-A1 | MERCAPTOAMIDINE DERIVATIVES AND METHODS OF USE | HNMT, HRH2, HRH4 | ALOX15 486/4885HSD17B10 2248/4885CA12 1503/4885 |
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | CXCR4, CXCR1, CXCL12 | ALOX15 3070/4885HSD17B10 4073/4885CA12 4512/4885 |
| US-20160130282-A1 | MERCAPTOAMIDINE DERIVATIVES AND METHODS OF USE | HNMT, HRH2, HRH4 | ALOX15 486/4885HSD17B10 2248/4885CA12 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.